Designed for selectivity

JUVMO is a first-of-its-kind selective D1/D5 agonist^1*

D1/D5 receptors regulate motor activity, cognitive functions, and reward, while D2/D3/D4 receptors regulate motor activity, cognitive functions, learning, impulse control, sleep, and food intake^2,3

JUVMO mechanism of action^1,4

Transcript

Current dopaminergic treatments for Parkinson’s often have binding affinities at D2, D3, or D4 receptors

Pinch to zoom

	D1-Like Family		D2-Like Family
	D1	D5	D2	D3	D4
JUVMO^1,4
Pramipexole⁵
Ropinirole⁵
Rotigotine⁶

JUVMO is a once-daily PD medication with a 24-hour half-life^1†

^*JUVMO acts as a selective partial agonist by binding to D1 and D5 receptors with nanomolar affinity, eliciting 65% and 81% of dopamine’s intrinsic activity, respectively.^1,4

^†Please see Prescribing Information on dose modifications for CYP3A inducers and inhibitors.

AI-generated depiction. Not a real patient.

Explore JUVMO’s efficacy as adjunctive therapy to oral levodopa and monotherapy

Explore efficacy

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hypotension/Orthostatic Hypotension: Patients with Parkinson's disease may have an impaired capacity to respond to an orthostatic challenge. In clinical studies and clinical experience, dopaminergic medications appear to impair the systemic regulation of blood pressure, resulting in hypotension and/or orthostatic hypotension, especially during dose escalation. Patients with PD treated with JUVMO (tavapadon) should be monitored for signs and symptoms of hypotension/orthostatic hypotension, especially during dose escalation, and should be informed of this risk.

Impulse Control/Compulsive Behaviors: Patients may experience intense urges while on JUVMO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while on JUVMO. Consider reducing the dose or discontinuing JUVMO if a patient develops such urges.

Hallucinations and Psychotic-like Behavior: Medications for the treatment of PD, including JUVMO, can have effects on thinking and behavior. Age appears to increase the risk of hallucinations in patients taking JUVMO. The risk of hallucination may be increased when JUVMO is co-administered with strong CYP3A inhibitors during the maintenance phase. Consider the risks and benefits prior to initiating treatment with JUVMO in patients with a major psychotic disorder because of the risk of exacerbating psychosis. Consider stopping JUVMO if hallucinations or psychotic-like behaviors occur.

Dyskinesia: JUVMO may cause or exacerbate pre-existing dyskinesia. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.

Adverse Reactions

The most common adverse reactions (≥5%) for JUVMO without levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.

The most common adverse reactions (≥5%) for JUVMO with levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Drug Interactions

Strong CYP3A Inducers: Avoid use with JUVMO. Strong and moderate CYP3A inhibitors: avoid use with JUVMO during titration; JUVMO dosage modification is recommended during maintenance. Moderate CYP3A Inducers: JUVMO dosage modification is recommended during titration and maintenance. Consult the full Prescribing Information for JUVMO for more information on drug interactions and recommended dosage modifications.

Dosage Forms and Strengths

JUVMO is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see full Prescribing Information.

INDICATION

JUVMO is indicated for the treatment of Parkinson’s disease in adults.

US-TAV-260171

References:

JUVMO [package insert]. North Chicago, IL: AbbVie Inc.
Bhatia A, Lenchner JR, Saadabadi A. Biochemistry, Dopamine Receptors. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 22, 2023.
Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S. Dopamine agonists in Parkinson’s disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clin Park Relat Disord. 2023;9:100212. doi:10.1016/j.prdoa.2023.100212
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S. Rationale and development of tavapadon, a D1/D5-selective partial dopamine agonist for the treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets. 2024;23(4):476-487. doi:10.2174/1871527322666230331121028
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791-804. doi:10.1124/jpet.102.039867
Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73-86. doi:10.1007/s00210-008-0341-4

TEMPO-1 baseline characteristics¹

TEMPO-1 (N=529)

Pinch to zoom

	JUVMO 5 mg (n=177)	JUVMO 15 mg (n=177)	Placebo (n=175)
Age (years), Mean (SD)	63.7 (9.8)	63.8 (9.4)	63.5 (9.6)
Age Group, n (%)
<65 years	48.0%	46.9%	49.1%
≥65 years	52.0%	53.1%	50.9%
Years Since Initial Diagnosis, Mean (SD)	0.75 (0.84)	0.76 (0.80)	0.69 (0.77)
Baseline MDS-UPDRS Score, Mean (SD)
Part II	7.1 (4.0)	7.7 (4.2)	7.4 (3.8)
Part III	24.1 (8.6)	24.3 (9.1)	24.7 (8.1)
Parts II + III	31.3 (10.9)	32.1 (11.6)	32.0 (10.0)
MAO-B Inhibitor Use at Baseline	26.6%	27.1%	24.0%

MAO-B=monoamine oxidase-B; MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; SD=standard deviation.

TEMPO-2 baseline characteristics¹

TEMPO-2 (N=304)

Pinch to zoom

	JUVMO 5-15 mg (n=151)	Placebo (n=153)
Age (years), Mean (SD)	63.1 (9.0)	62.6 (9.4)
Age Group, n (%)
<65 years	51%	54%
≥65 years	49%	46%
Years Since Initial Diagnosis, Mean (SD)	0.88 (0.78)	0.85 (0.81)
Baseline MDS-UPDRS Score, Mean (SD)
Part II	7.4 (4.3)	6.9 (3.9)
Part III	23.6 (8.8)	23.1 (8.9)
Parts II + III	31.1 (11.2)	30.0 (11.1)
MAO-B Inhibitor Use at Baseline	30.5%	29.4%

MAO-B=monoamine oxidase-B; MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; SD=standard deviation.

TEMPO-3 baseline characteristics¹

TEMPO-3 (N=507)

Pinch to zoom

	JUVMO 5-15 mg (N=252)	Placebo (N=255)
Age (years), Mean (SD)	65.6 (8.4)	64.1 (8.5)
Age Group, n (%)
<65 years	41.3%	46.7%
≥65 years	58.7%	53.3%
Years Since Initial Diagnosis, Mean (SD)	6.9 (4.5)	6.4 (4.6)
Baseline MDS-UPDRS Part II Score, Mean (SD)	13.3 (6.5)	12.5 (7.1)
Daily LD dose (mg), Mean (SD)	811.9 (451.4)	817.6 (644.0)
Daily “On” time without troublesome dyskinesia (hours), Mean (SD)	9.9 (2.6)	10.1 (2.6)
Daily “Off” time (hours), Mean (SD)	5.6 (2.2)	5.4 (2.5)

LD=levodopa; MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; SD=standard deviation.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Dyskinesia: JUVMO may cause or exacerbate pre-existing dyskinesia. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.

Adverse Reactions

The most common adverse reactions (≥5%) for JUVMO without levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety.

The most common adverse reactions (≥5%) for JUVMO with levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension.

Drug Interactions

Dosage Forms and Strengths

JUVMO is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see full Prescribing Information.

INDICATION

JUVMO is indicated for the treatment of Parkinson’s disease in adults.

US-TAV-260171

D1/D5 selectivity in Parkinson's treatment

Designed for selectivity

JUVMO is a first-of-its-kind selective D1/D5 agonist1*

JUVMO mechanism of action1,4

Current dopaminergic treatments for Parkinson’s often have binding affinities at D2, D3, or D4 receptors

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Adverse Reactions

Drug Interactions

Dosage Forms and Strengths

INDICATION

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Adverse Reactions

Drug Interactions

Dosage Forms and Strengths

INDICATION

JUVMO is a first-of-its-kind selective D1/D5 agonist^1*

JUVMO mechanism of action^1,4